Stock MIRA MIRA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages MIRA Pharmaceuticals, Inc.

Equities

MIRA

US60458C1045

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-06-14 EDT 		5-day change 1st Jan Change
0.738 USD +3.93% Intraday chart for MIRA Pharmaceuticals, Inc. -2.89% -29.71%
06-10 MIRA Pharmaceuticals, Inc. Announces Positive Preclinical Study Results for Its Novel Oral Ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year CI
05-29 Sector Update: Health Care Stocks Fall Late Afternoon MT

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
MIRA Pharmaceuticals, Inc. Announces Positive Preclinical Study Results for Its Novel Oral Ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year
Sector Update: Health Care Stocks Fall Late Afternoon
Sector Update: Health Care Stocks Retreat Wednesday Afternoon
Mira Pharmaceuticals Says US DEA Finds Marijuana Analog a Non-Controlled Substance
MIRA Pharmaceuticals, Inc. Announces DEA Rules Mira-55, A Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as A Controlled Substance
Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, A Differentiated Oral Ketamine Analog
MIRA Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Mira Pharmaceuticals, Inc. Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission
MIRA Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Mira Pharmaceuticals Inc. Announces Appointment of Itzchak Angel as Chief Scientific Advisor
MIRA Pharmaceuticals, Inc. Announces Management Changes
MIRA Pharmaceuticals, Inc. Provides Updated Information Regarding the Patented, Pre-Clinical Drug Candidate Molecule Known as Mira1a
MIRA Pharmaceuticals, Inc. Announces Resignation of Christos Nicholoudis from the Board of Directors and as Part-Time General Counsel
MIRA Pharmaceuticals, Inc. Releases Breakthrough Data from Artificial Intelligence Simulations
Sector Update: Health Care Stocks Advance in Late Afternoon Trading
Top MIdday Gainers
Sector Update: Health Care Stocks Advance in Afternoon Trading
Sector Update: Health Care
Mira Pharmaceuticals Signs Licensing Deal for Ketamine Analog Ketamir-2
MIRA Pharmaceuticals, Inc. Approves Appointment of Michael Jerman to the Board
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MIRA Stock
  4. News MIRA Pharmaceuticals, Inc.
  5. Other languages